Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition

作者：Mina Chatran, Younes Pilehvar‐Soltanahmadi, Mehdi Dadashpour, Leila Faramarzi, Sara Rasouli, Davoud Jafari-Gharabaghlou, Navid Sarakhs Asbaghi, Nosratollah Zarghami · 发表于：Drug Research · 年份：2018 · DOI：10.1055/a-0631-8046 · 被引用次数：56 · 研究领域：Metabolism, Diabetes, and Cancer、Silymarin and Mushroom Poisoning、Protein Kinase Regulation and GTPase Signaling

BACKGROUND: There is a growing body of data that chemotherapeutic combination strategies would be more effective in reducing drug toxicity, inhibiting tumor progression in comparison to either drug alone. OBJECTIVE: To explore a chemopreventive strategy for improving breast cancer treatment efficacy, the anticancer effects of a combination of Metformin (MET) and Silibinin (SIL) were investigated in T47D breast cancer cells. MATERIALS AND METHODS: Cytotoxicity of the drugs individually and in combination was evaluated using MTT assay. The precise nature of the interaction between MET and SIL was further analyzed through the median-effect method. In addition, qRT-PCR was applied to determine the expression levels of hTERT and cyclin D1 genes after 48 h drug exposure. RESULTS: MTT assays showed that MET and SIL individually inhibited the cell viability in a dose and time-dependent manner, and the obtained combination indices (CIs) were<1 for all the combination treatments, indicating that the anticancer agents synergistically induced growth inhibition in the breast cancer cells. qPCR findings revealed that the drug combination also synergistically down-regulated the expression levels of hTERT and cyclin D1 at all used concentrations compared with the drugs used alone after 48 h treatment (P≤0.05). CONCLUSION: The results provide evidence that synergistic antiproliferative effects of MET and SIL, linking to the down-regulation of Cyclin D1 and hTERT genes, and propose that MET+SI...